arrow
F

Frauke Stascheit

department of neurology with experimental neurology
H指数:14
被引数:1,268

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multicentric prognostic observational study on biomarker profile in immunotherapy-naïve patients with highly active generalized myasthenia gravis (PROGNO-MG): a study protocol

多中心预后观察性研究:评估免疫治疗初治的高活动性全身型重症肌无力患者中的生物标志物谱(PROGNO-MG):一项研究方案

2026-05-120
OAAI
Complement Inhibition Therapy in Myasthenic Crisis—A Multicentre Retrospective Analysis of 17 Cases From Germany

重症肌无力危象中的补体抑制疗法——来自德国的17例多中心回顾性分析

2026-04-150
OA
Clinical course and prognosis of chronic autoimmune neuropathies requiring intensive care: a retrospective cohort study

慢性自身免疫性神经病变需要重症监护的临床病程和预后:一项回顾性队列研究

2026-02-250
OAAI
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

拉伏珠单抗和阿巴西普对经典和替代补体通路的抑制

2025-11-010
OAAI
AXIN1, STAMBP, ST1A1, CDCP1, and SIRT2 Validated as Myasthenia Gravis Biomarkers: A Comparative Proteomic Study With MS, CIDP, and Controls

AXIN1、STAMBP、ST1A1、CDCP1和SIRT2被验证为重症肌无力生物标志物:一项与多发性硬化、慢性炎性脱髓鞘性多发性神经根神经病和对照组的比较蛋白质组学研究

2025-11-010
OAAI
Calprotectin and neurofilament serum levels correlate with treatment response in myasthenia gravis under intensified therapy–A pilot study

钙卫蛋白和神经丝蛋白血清水平与重症肌无力在强化治疗下的治疗反应相关——一项试点研究

2025-09-090
OAAI
278th ENMC International Workshop: European standards for harmonization of myasthenia gravis registries and emerging digital solutions. 20th-21st September 2024, Hoofddorp, The Netherlands

第278届ENMC国际研讨会:重症肌无力登记系统的欧洲标准化与新兴数字解决方案。2024年9月20日至21日,荷兰霍夫多普。

2025-06-010
PRE
Toward European harmonization of national myasthenia gravis registries: modified Delphi procedure-based expert consensus on collectable data
2025-03-110
OAAI
C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis

C5补体抑制与FcRn调节在全身性重症肌无力中的作用

2025-01-110
PRE
Identi fi cation of disease phenotypes in acetylcholine receptor-antibody myasthenia gravis using proteomics-based consensus clustering

使用基于蛋白质组学的共识聚类识别乙酰胆碱受体-抗体型重症肌无力的疾病表型

2024-07-012
OAAI
Inter-alpha-trypsin inhibitor heavy chain H3 is a potential biomarker for disease activity in myasthenia gravis

间 α-胰蛋白酶抑制剂重链H3是重症肌无力疾病活动的潜在生物标志物

2024-06-180
OAAI
Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients
2022-04-1253
OAAI